Anonymous
Guest
Anonymous
Guest
Today's Wall Street Journal reports that the US Court of Appeals for the Federal Circuit has overturned the recent judgment that Myriad could not patent the BRCA 1 and 2 genes, basing its analysis on molecules rather than the DNA contained in the genes. The case is very likely to go to the Supreme Court.